Last reviewed · How we verify
NCT05433467: CTMH
CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection
NA trial testing CT-guided localization for micro hepatocellular carcinoma before surgical resection in Cirrhosis, Liver in 5 participants. Currently enrolling.
30 April 2026
Quick facts
| Lead sponsor | Northern Jiangsu People's Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 1 May 2022 |
| Primary completion | 30 April 2026 |
| Estimated completion | 30 April 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- CT-guided localization for micro hepatocellular carcinoma before surgical resection
Conditions studied
- Cirrhosis, Liver — all drugs for Cirrhosis, Liver →
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
Northern Jiangsu People's Hospital
Who can join
18 and older, any sex, with Cirrhosis, Liver or Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this project, the preoperative anatomical location of micro hepatocellular carcinoma under the guidance of CT can provide guidance for accurate surgical resection. It may also shorten the operation time and reduce intraoperative bleeding.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05433467
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cirrhosis, Liver
Currently open trials in the same condition.
- NCT07286643 — Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol Sepsis · NA · recruiting
- NCT06871111 — The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial · Phase 1 · recruiting
- NCT07122700 — Evaluation of Non-Invasive Tests for Metabolic Liver Disease · recruiting
- NCT07051369 — Frequency of Portal Hypertension Among Patient With Cirrhotic Liver With Ultrasound · active not recruiting
- NCT06908785 — Utility of ROTEM® for Risk Stratification of Post-Invasive Procedure Hemorrhage in Patients With Cirrhosis (CIR-ROTEM) · recruiting
Other Northern Jiangsu People's Hospital trials
Trials by the same sponsor.
- NCT07490405 — Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism · NA · not yet recruiting
- NCT07461532 — Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD · NA · recruiting
- NCT07461545 — Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS · NA · recruiting
- NCT07462091 — Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection · NA · recruiting
- NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05433467 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northern Jiangsu People's Hospital
- Last refreshed: 13 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05433467.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing